J 2022

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

MOHAMED, Lounis, Rais Mohammed AMIR, Bencherit DJIHAD, Aouissi Hani AMIR, Oudjedi ADDA et. al.

Basic information

Original name

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

Authors

MOHAMED, Lounis, Rais Mohammed AMIR, Bencherit DJIHAD, Aouissi Hani AMIR, Oudjedi ADDA, Jitka KLUGAROVÁ (203 Czech Republic, belonging to the institution), Andrea POKORNÁ (203 Czech Republic, belonging to the institution), Miloslav KLUGAR (203 Czech Republic, belonging to the institution) and Abanoub RIAD (818 Egypt, guarantor, belonging to the institution)

Edition

Frontiers in Public Health, LAUSANNE, FRONTIERS MEDIA SA, 2022, 2296-2565

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30304 Public and environmental health

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00125821

Organization unit

Faculty of Medicine

DOI

UT WoS

000803613500001

Keywords in English

adenoviral-based vaccine; COVID-19; health workers; inactivated virus vaccine; side effects

Tags

Tags

International impact, Reviewed
Změněno: 5/4/2023 08:16, Mgr. Tereza Miškechová

Abstract

V originále

Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20–30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.

Links

EF19_073/0016943, research and development project
Name: Interní grantová agentura Masarykovy univerzity
LTC20031, research and development project
Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST
MUNI/A/1402/2021, interní kód MU
Name: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
Investor: Masaryk University
MUNI/IGA/1104/2021, interní kód MU
Name: COVID-19 Vaccines Safety Tracking in the Czech Republic (Acronym: CoVaST-CZ)
Investor: Masaryk University